Cargando…

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

BACKGROUND: AdCD40L is an immunostimulatory gene therapy under evaluation for advanced melanoma, including ocular melanoma. Herein, we present the final data of a Phase I/IIa trial using AdCD40L alone or in combination with low dose cyclophosphamide +/- radiation therapy. METHODS: AdCD40L is a repli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irenaeus, Sandra, Schiza, Aglaia, Mangsbo, Sara M., Wenthe, Jessica, Eriksson, Emma, Krause, Johan, Sundin, Anders, Ahlström, Håkan, Tötterman, Thomas H., Loskog, Angelica, Ullenhag, Gustav J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667983/ https://www.ncbi.nlm.nih.gov/pubmed/29108250 http://dx.doi.org/10.18632/oncotarget.19750

Ejemplares similares

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
por: Loskog, Angelica, et al.
Publicado: (2016)

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
por: Schiza, Aglaia, et al.
Publicado: (2019)

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
por: Schiza, A., et al.
Publicado: (2017)

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
por: Eriksson, Emma, et al.
Publicado: (2016)

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023)

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020)

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
por: Labani-Motlagh, Alireza, et al.
Publicado: (2021)

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
por: Wenthe, Jessica, et al.
Publicado: (2022)

Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
por: Loskog, Angelica
Publicado: (2015)

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
por: Sandin, Linda C, et al.
Publicado: (2014)

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
por: Eriksson, E, et al.
Publicado: (2017)

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
por: Wenthe, Jessica, et al.
Publicado: (2021)

Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma
por: Mosavi, Firas, et al.
Publicado: (2013)

Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up
por: Saellstrom, Sara, et al.
Publicado: (2021)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
por: Sjöholm, Therese, et al.
Publicado: (2022)

Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
por: Sjöholm, Therese, et al.
Publicado: (2023)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
por: Elmetwali, Taha, et al.
Publicado: (2020)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Euonymus alatus (Thunb.) Siebold leaf extract enhanced immunostimulatory effects in a cyclophosphamide-induced immunosuppressed rat model
por: Shin, Dong Yeop, et al.
Publicado: (2023)

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
por: Ellmark, Peter, et al.
Publicado: (2016)

Immunostimulatory Effect of Zanthoxylum schinifolium-Based Complex Oil Prepared by Supercritical Fluid Extraction in Splenocytes and Cyclophosphamide-Induced Immunosuppressed Rats
por: Lee, Hak Yong, et al.
Publicado: (2018)

Cancer treatment of today in view of the Nobel Prize
por: Ullenhag, Gustav
Publicado: (2018)

Antioxidant and Immunostimulatory Activities of Fermented Sour Soybean Milk Added With Polypeptides From Pleurotus eryngii
por: Song, Xinling, et al.
Publicado: (2022)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Injectable Nanoparticle‐Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies
por: Correa, Santiago, et al.
Publicado: (2022)

A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

De novo metastatic breast cancer in men vs women: a Swedish population-based cohort study
por: Schiza, Aglaia, et al.
Publicado: (2023)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
por: Sarén, Tina, et al.
Publicado: (2023)

Trial Watch: Immunostimulatory cytokines
por: Vacchelli, Erika, et al.
Publicado: (2012)

Trial Watch: Immunostimulatory cytokines
por: Vacchelli, Erika, et al.
Publicado: (2013)

Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility
por: Liu, Xiaobo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2ab7fbqb74b53q5ec6m9dbi1nd